Rituximab-mediated Sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

被引:42
作者
Emmanouilides, C
Jazirehi, AR
Bonavida, B
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Div Oncol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
non-Hodgkin's lymphoma; sensitization; apoptosis; drug-resistance;
D O I
10.1089/108497802320970226
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-Hodgkin's lymphoma (NHL) responds initially to chemotherapy, however, the disease often relapses and acquires a chemoresistant phenotype. Third line treatment options such as paclitaxel, gemcitabine, and vinorelbine have been tried in patients with refractory or relapsed NHL with antilymphoma activity. Currently, rituximab (anti-CD20) has been approved for treatment of indolent NHL, with significant activity in a wide spectrum of B-cell malignancies, though a percentage of patients do not respond to rituximab treatment. Previous findings from our laboratory have demonstrated that rituximab can sensitize drug-resistant NHL B-lymphoma in vitro to some chemotherapeutic drugs. Hence, in this study, we examined the effect of combination treatment of rituximab and the drugs paclitaxel, gemcitabine, and vinorelbine on various NHL cell lines. Our findings indicate that pretreatment of NHL tumor cells with rituximab sensitizes drug-resistant NHL tumor cells to drug-mediated cytotoxicity. These findings suggest the potential clinical application of combination treatments of rituximab and paclitaxel, gemcitabine or vinorelbine in the treatment of drug/rituximab refractory non-Hodgkin's lymphoma.
引用
收藏
页码:621 / 630
页数:10
相关论文
共 47 条
  • [1] Alas S, 2000, ANTICANCER RES, V20, P2961
  • [2] Alas S, 2001, CLIN CANCER RES, V7, P709
  • [3] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
    Anderson, DR
    GrilloLopez, A
    Varns, C
    Chambers, KS
    Hanna, N
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 705 - 708
  • [4] Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma
    Balzarotti, M
    Santoro, A
    Tondini, C
    Fornier, M
    Bonadonna, G
    [J]. ANNALS OF ONCOLOGY, 1996, 7 (09) : 970 - 972
  • [5] Gemcitabine: A pharmacologic and clinical overview
    Barton-Burke, M
    [J]. CANCER NURSING, 1999, 22 (02) : 176 - 183
  • [6] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    Berinstein, NL
    Grillo-Lopez, AJ
    White, CA
    Bence-Bruckler, I
    Maloney, D
    Czuczman, M
    Green, D
    Rosenberg, J
    McLaughlin, P
    Shen, D
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 995 - 1001
  • [7] Chassagne-Clément C, 1999, B CANCER, V86, P529
  • [8] Coiffier B, 1998, BLOOD, V92, P1927
  • [9] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [10] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    Demidem, A
    Lam, T
    Alas, S
    Hariharan, K
    Hanna, N
    Bonavida, B
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) : 177 - 186